The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
about
Atypical hemolytic uremic syndromeClinical features of anti-factor H autoantibody-associated hemolytic uremic syndromeHemolytic uremic syndrome: new developments in pathogenesis and treatmentRelative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotypeIdentification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritisAssociation of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeClinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaExcessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time?Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?Factor H and CFHR1 polymorphisms associated with atypical Haemolytic Uraemic Syndrome (aHUS) are differently expressed in Tunisian and in Caucasian populations.Thrombotic microangiopathy and associated renal disorders.Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndromeComplement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.DGKE and atypical HUS.Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.Successful treatment of DEAP-HUS with eculizumab.Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literatureThe major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012.Anti-complement-factor H-associated glomerulopathies.Atypical Hemolytic Uremic Syndrome: A Brief Review.Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32.Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families.Oxidative stress, innate immunity, and age-related macular degenerationThe Genetics of Ultra-Rare Renal Disease.Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.Recent insights into C3 glomerulopathyFactor h: a complement regulator in health and disease, and a mediator of cellular interactions.A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency.Mini review: A unique case of crescentic C3 glomerulonephritis.Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandEffective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies.Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab.Deletion Variants of CFHR1 and CFHR3 Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy.
P2860
Q21202864-85CE6796-1130-4D6F-BDA4-B329AFC3F043Q24606843-57F546C7-D6DD-44C0-9F04-C0FD6B66D410Q24613517-B9F28EAE-2D26-49A5-A61C-6E3620842869Q24613907-65292DCA-DFBD-491C-BE78-FD14A3F4A7E0Q24615589-AC827093-700E-4334-B345-C9D9193AFE24Q24634697-A80A8046-AEDE-4F4D-BE02-99C636D71218Q26739894-9605A513-29E3-40CA-97F2-4FD4F48F012EQ33388046-56A8B09E-3879-4A20-866E-47B66CC0722DQ33388474-25BED17B-1719-42FE-B088-99C9A92583A8Q33395774-8BF4F419-F199-417A-866D-DC737D9037EEQ33398546-A9CCE2AD-A009-4EEB-96FC-E54C34525ACFQ33402372-73B9771C-FC9F-4078-B9EB-8E0675BD983FQ33402827-5081DEA2-2FCF-4229-8AC1-AE2F0DF4F881Q33404847-4B7F1F9B-71CA-484B-98DD-D667389DFACBQ33406025-AD6349DF-7685-4142-81CF-54AF8D90371DQ33407312-58844343-51CD-46D3-96E3-D81729308252Q33408171-84F60E95-9F6D-4D66-99CC-430CC321B704Q33409198-9B54EE7D-6759-4207-98FF-5F7404902243Q33411577-D7648CBC-7958-44D4-87FC-EEF7282EA64FQ33417375-4210666E-EB58-4E31-9E04-E7897003DA1CQ33419812-0A9DCE12-FA9C-4BF4-BF96-272C7C1FFEAEQ33420213-614ADC5B-CC10-4B5C-A7AE-10F515892EB1Q33422650-C3C36123-929C-4471-A135-04052663C126Q33432215-11BD7193-7815-4D14-BC26-234A7AC82612Q33434103-4833AB83-14D4-44DB-B850-DF42AFB8CE7BQ33442794-8423436E-03C0-4300-8BA2-325033C0DF5DQ34683659-08FCCF95-4387-44ED-84E5-DE04CD62962DQ35026701-99791559-CB82-4B4A-8119-DEC9F3E1B6D9Q36940296-29FFCDD6-733D-4B63-B1D8-52A0E0F7A198Q37032691-AC5C5753-19D1-41B0-B94C-8311EB92042EQ37546464-F14D1F55-18F3-4D75-A685-0E455BDFA1C9Q37727489-CDA60FAC-7F94-4582-9C56-A10B1CB50CD0Q38088187-65B82B97-3377-45D4-B11A-7114D31B379DQ38223669-D51DDD24-F860-42AF-AA31-831EFFE6B7B8Q38783519-F22FBAD0-7B17-40E8-8D1A-4FCE918F1221Q39138224-60FDB263-54AD-4BB4-926C-2773D8BCB796Q42650328-68E1283B-46E5-4A4C-A37F-5D53993B6097Q47096270-4A715605-3A67-48C8-8D92-BF01006F1D6BQ47144302-9C0CF743-A938-4F74-B713-A14111735BD1Q47428540-AA37B6D4-BD5B-41A8-8BC5-C5204BA3E54C
P2860
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The high frequency of compleme ...... l haemolytic uraemic syndrome.
@ast
The high frequency of compleme ...... l haemolytic uraemic syndrome.
@en
type
label
The high frequency of compleme ...... l haemolytic uraemic syndrome.
@ast
The high frequency of compleme ...... l haemolytic uraemic syndrome.
@en
prefLabel
The high frequency of compleme ...... l haemolytic uraemic syndrome.
@ast
The high frequency of compleme ...... l haemolytic uraemic syndrome.
@en
P2093
P50
P356
P1476
The high frequency of compleme ...... al haemolytic uraemic syndrome
@en
P2093
V Frémeaux-Bacchi
P304
P356
10.1136/JMG.2008.064766
P407
P577
2009-05-11T00:00:00Z